Eli Lilly and Company (LLY) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Eli Lilly and Company Revenue Highlights

Latest Revenue (Y)

$34.12B

Latest Revenue (Q)

$11.44B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Eli Lilly and Company Revenue by Period

Eli Lilly and Company Revenue by Year

Date	Revenue	Change
2023-12-31	$34.12B	19.56%
2022-12-31	$28.54B	0.79%
2021-12-31	$28.32B	15.40%
2020-12-31	$24.54B	9.95%
2019-12-31	$22.32B	3.84%
2018-12-31	$21.49B	-6.03%
2017-12-31	$22.87B	7.77%
2016-12-31	$21.22B	6.33%
2015-12-31	$19.96B	1.75%
2014-12-31	$19.62B	-15.13%
2013-12-31	$23.11B	2.25%
2012-12-31	$22.60B	-6.93%
2011-12-31	$24.29B	5.25%
2010-12-31	$23.08B	5.68%
2009-12-31	$21.84B	7.15%
2008-12-31	$20.38B	9.36%
2007-12-31	$18.63B	18.75%
2006-12-31	$15.69B	7.14%
2005-12-31	$14.65B	5.68%
2004-12-31	$13.86B	10.14%
2003-12-31	$12.58B	13.59%
2002-12-31	$11.08B	-4.03%
2001-12-31	$11.54B	6.26%
2000-12-31	$10.86B	8.59%
1999-12-31	$10.00B	8.29%
1998-12-31	$9.24B	8.44%
1997-12-31	$8.52B	15.94%
1996-12-31	$7.35B	8.62%
1995-12-31	$6.76B	18.42%
1994-12-31	$5.71B	-11.48%
1993-12-31	$6.45B	-

Eli Lilly and Company generated $34.12B in revenue during NA 2023, up 19.56% compared to the previous quarter, and up 158.77% compared to the same period a year ago.

Eli Lilly and Company Revenue by Quarter

Date	Revenue	Change
2024-09-30	$11.44B	1.21%
2024-06-30	$11.30B	28.91%
2024-03-31	$8.77B	-6.26%
2023-12-31	$9.35B	-1.53%
2023-09-30	$9.50B	14.27%
2023-06-30	$8.31B	19.43%
2023-03-31	$6.96B	-4.68%
2022-12-31	$7.30B	5.19%
2022-09-30	$6.94B	6.99%
2022-06-30	$6.49B	-16.93%
2022-03-31	$7.81B	-2.37%
2021-12-31	$8.00B	18.12%
2021-09-30	$6.77B	0.49%
2021-06-30	$6.74B	-0.96%
2021-03-31	$6.81B	-8.53%
2020-12-31	$7.44B	29.60%
2020-09-30	$5.74B	4.39%
2020-06-30	$5.50B	-6.15%
2020-03-31	$5.86B	-4.16%
2019-12-31	$6.11B	11.64%
2019-09-30	$5.48B	-2.84%
2019-06-30	$5.64B	10.69%
2019-03-31	$5.09B	-20.91%
2018-12-31	$6.44B	6.21%
2018-09-30	$6.06B	-4.62%
2018-06-30	$6.36B	11.49%
2018-03-31	$5.70B	-7.48%
2017-12-31	$6.16B	8.88%
2017-09-30	$5.66B	-2.86%
2017-06-30	$5.82B	11.40%
2017-03-31	$5.23B	-9.24%
2016-12-31	$5.76B	10.96%
2016-09-30	$5.19B	-3.94%
2016-06-30	$5.40B	11.09%
2016-03-31	$4.87B	-9.50%
2015-12-31	$5.38B	8.39%
2015-09-30	$4.96B	-0.38%
2015-06-30	$4.98B	7.19%
2015-03-31	$4.64B	-9.31%
2014-12-31	$5.12B	5.04%
2014-09-30	$4.88B	-1.22%
2014-06-30	$4.94B	5.39%
2014-03-31	$4.68B	-19.38%
2013-12-31	$5.81B	0.63%
2013-09-30	$5.77B	-2.65%
2013-06-30	$5.93B	5.85%
2013-03-31	$5.60B	-5.97%
2012-12-31	$5.96B	9.44%
2012-09-30	$5.44B	-2.81%
2012-06-30	$5.60B	-0.02%
2012-03-31	$5.60B	-7.35%
2011-12-31	$6.05B	-1.65%
2011-09-30	$6.15B	-1.68%
2011-06-30	$6.25B	7.08%
2011-03-31	$5.84B	-5.62%
2010-12-31	$6.19B	9.41%
2010-09-30	$5.65B	-1.63%
2010-06-30	$5.75B	4.80%
2010-03-31	$5.49B	-7.56%
2009-12-31	$5.93B	6.69%
2009-09-30	$5.56B	5.09%
2009-06-30	$5.29B	4.87%
2009-03-31	$5.05B	-3.14%
2008-12-31	$5.21B	0.02%
2008-09-30	$5.21B	1.15%
2008-06-30	$5.15B	7.13%
2008-03-31	$4.81B	-7.36%
2007-12-31	$5.19B	-

Eli Lilly and Company generated $11.44B in revenue during Q3 2024, up 1.21% compared to the previous quarter, and up 137.62% compared to the same period a year ago.

Eli Lilly and Company Revenue Breakdown

Eli Lilly and Company Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Product	$28.81B	$25.46B	$25.96B	$22.69B	$20.38B
Collaboration and Other Revenue	$5.31B	$3.08B	$2.36B	$1.84B	$1.94B
Trajenta (BI)	-	$383.70M	-	-	-
Royalty	-	$163.40M	$175.00M	$135.60M	$301.50M
COVID-19 Antibodies	-	-	$2.24B	-	-
TYVYT	-	-	-	$308.70M	-

Eli Lilly and Company's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (84.44%), and Collaboration and Other Revenue (15.56%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Neuroscience	$351.80M	$389.10M	$1.77B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Oncology	$2.23B	$1.81B	$1.75B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Product	$53.20M	$41.30M	$42.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Immunology	$1.19B	$834.00M	$986.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Baqsimi	-	-	$13.10M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diabetes	-	-	$4.72B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Neuroscience	-	-	$118.20M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Oncology	-	-	$275.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cialis	-	-	$86.80M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Immunology	-	-	$11.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Diabetes	-	-	$141.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Olumiant	-	-	$231.40M	$406.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mounjaro	-	-	$1.41B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Jardiance	-	-	$700.80M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Humulin	-	-	$206.70M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Humalog	-	-	$395.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Forteo	-	-	$146.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erbitux	-	-	$153.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Emgality	-	-	$168.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cyramza	-	-	$224.10M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
COVID-19 Antibodies	-	-	-	$1.06B	$217.10M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Basaglar	-	-	$179.60M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Alimta	-	-	$53.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Zyprexa	-	-	$1.48B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Verzenio	-	-	$1.04B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Trulicity	-	-	$1.67B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Taltz	-	-	$744.20M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Trajenta (BI)	-	-	-	$103.60M	$85.80M	$90.70M	$103.80M	$92.60M	$96.10M	-	-	-	-	-	-	-	-	-	-	-
Collaboration and Other Revenue	-	-	-	$1.33B	$721.80M	$962.00M	$822.40M	$617.10M	$677.10M	$621.50M	$669.60M	$485.60M	$507.50M	$459.50M	$421.70M	$456.30M	$579.70M	$494.60M	$468.00M	-
Product	-	-	-	$6.98B	$6.24B	$6.34B	$6.12B	$5.87B	$7.13B	$7.38B	$6.07B	$6.32B	$6.93B	$5.28B	$5.08B	$5.40B	$5.53B	$4.98B	$5.17B	-
Royalty	-	-	-	$30.30M	$25.10M	$32.50M	$43.30M	$34.40M	$53.20M	$38.90M	$31.00M	$43.00M	$34.10M	$31.50M	$34.70M	$35.40M	$138.50M	$67.90M	$59.60M	-
TYVYT	-	-	-	-	-	-	-	-	-	-	$125.60M	-	-	-	-	-	-	-	-	-

Eli Lilly and Company's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Oncology (58.39%), Immunology (31.02%), Neuroscience (9.20%), and Other Product (1.39%).

Eli Lilly and Company Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
UNITED STATES	$21.79B	$18.19B	-	-	-
CHINA	$1.54B	$1.45B	$1.66B	$1.12B	-
Europe	$6.17B	$4.30B	$4.78B	$4.19B	$3.77B
JAPAN	$1.67B	$1.75B	$2.37B	$2.58B	$2.55B
Other Foreign Countries	$2.95B	$2.85B	$2.70B	$2.42B	$3.28B

Eli Lilly and Company's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (63.86%), Europe (18.09%), Other Foreign Countries (8.63%), JAPAN (4.90%), and CHINA (4.51%).

Quarterly Revenue by Country

Country	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
JAPAN	$429.10M	$363.90M	$439.00M	$390.80M	$455.60M	$387.20M	$395.00M	$487.70M	$454.40M	$410.20M	$534.80M	$595.00M	$665.40M	$571.80M	$664.00M	$660.10M	$666.70M	$592.30M	$709.20M	$641.50M
Other Foreign Countries	$1.11B	$892.90M	$744.30M	$780.30M	$748.50M	$673.10M	$822.90M	$632.00M	$645.70M	$751.50M	$765.50M	$689.40M	$638.10M	$609.10M	$654.00M	$583.20M	$575.20M	$610.40M	$872.60M	$851.40M
UNITED STATES	$7.81B	$5.69B	$6.46B	$5.37B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Europe	$1.63B	$1.44B	$1.34B	$2.57B	$1.18B	$1.09B	$1.07B	$1.06B	$1.10B	$1.07B	$1.15B	$1.10B	$1.21B	$1.32B	$1.20B	$1.05B	$873.00M	$1.06B	$1.01B	$923.40M
CHINA	$459.90M	$376.20M	$377.20M	$390.80M	$399.00M	$372.70M	$350.80M	$343.40M	$352.10M	$406.50M	$376.40M	$400.30M	$522.50M	$362.20M	$320.70M	$289.10M	$239.80M	$267.30M	-	-

Eli Lilly and Company's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (68.31%), Europe (14.23%), Other Foreign Countries (9.69%), CHINA (4.02%), and JAPAN (3.75%).

Eli Lilly and Company Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
JNJ	Johnson & Johnson	$85.15B	$22.47B
MRK	Merck	$60.12B	$16.66B
PFE	Pfizer	$58.50B	$17.70B
ABBV	AbbVie	$54.32B	$14.46B
BMY	Bristol-Myers Squibb Company	$45.01B	$11.89B
LLY	Eli Lilly and Company	$34.12B	$11.44B
AMGN	Amgen	$28.19B	$8.50B
GILD	Gilead Sciences	$27.12B	$7.55B

LLY Revenue FAQ

What is Eli Lilly and Company’s yearly revenue?

Eli Lilly and Company's yearly revenue for 2023 was $34.12B, representing an increase of 19.56% compared to 2022. The company's yearly revenue for 2022 was $28.54B, representing an increase of 0.79% compared to 2021. LLY's yearly revenue for 2021 was $28.32B, representing an increase of 15.40% compared to 2020.

What is Eli Lilly and Company’s quarterly revenue?

Eli Lilly and Company's quarterly revenue for Q3 2024 was $11.44B, a 1.21% increase from the previous quarter (Q2 2024), and a 20.43% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $11.3B, a 28.91% increase from the previous quarter (Q1 2024), and a 35.98% increase year-over-year (Q2 2023). LLY's quarterly revenue for Q1 2024 was $8.77B, a -6.26% decrease from the previous quarter (Q4 2023), and a 25.98% increase year-over-year (Q1 2023).

What is Eli Lilly and Company’s revenue growth rate?

Eli Lilly and Company's revenue growth rate for the last 3 years (2021-2023) was 20.50%, and for the last 5 years (2019-2023) was 52.89%.

What are Eli Lilly and Company’s revenue streams?

Eli Lilly and Company's revenue streams in c 23 are Product, and Collaboration and Other Revenue. Product generated $28.81B in revenue, accounting 84.44% of the company's total revenue, up 13.16% year-over-year. Collaboration and Other Revenue generated $5.31B in revenue, accounting 15.56% of the company's total revenue, up 72.49% year-over-year.

What is Eli Lilly and Company’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Eli Lilly and Company was Product. This segment made a revenue of $28.81B, representing 84.44% of the company's total revenue.